Who is sponsoring NCT05747339?

NCT05747339 is sponsored by Wuxi People's Hospital.

What drugs are being tested in NCT05747339?

Interventions in NCT05747339: tumor treatment vaccine injection.

What condition does NCT05747339 study?

NCT05747339 studies Solid Tumors, Adult.

Is NCT05747339 still recruiting?

NCT05747339 is currently status unknown. Last updated 13 June 2023.

Last reviewed 2023-06-13 · How we verify

NCT05747339

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors

Status unknown NA Last updated 13 June 2023

What this trial tests

NA trial testing tumor treatment vaccine injection in Solid Tumors, Adult in 50 participants. Status unknown.

Timeline

7 June 2023

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Wuxi People's Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	7 June 2023
Primary completion	31 December 2024
Estimated completion	31 December 2024

Drugs / interventions tested

tumor treatment vaccine injection — full drug profile →

Conditions studied

Solid Tumors, Adult — all drugs for Solid Tumors, Adult →

Sponsor

Wuxi People's Hospital

Who can join

Adults 18 to 75, any sex, with Solid Tumors, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a study of the clinical efficacy and mechanism study of tumor treatment vaccine (TTV, also known as Neo-BCV) in patients with recurrent and refractory advanced solid tumors.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Neo-BCV: A Novel Bacterial Complex Vaccine Reshaping the Gut Microbiota to Enhance the Antitumor Immune Response.
Yang H, Zhu H, Zhu Z, Man L, et al · · 2026 · PMID 42042786 · DOI 10.3390/vaccines14040310
Neo-BCV: A Novel Bacterial Liquid Complex Vaccine for Enhancing Dendritic Cell-Mediated Immune Responses Against Lung Cancer.
Zhu Z, Chu Z, Fei F, Wu C, et al · · 2025 · PMID 39852843 · DOI 10.3390/vaccines13010064

Verify or expand the search:

Other recruiting trials for Solid Tumors, Adult

Currently open trials in the same condition.

NCT07396584 — HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor · Phase 1, PHASE2 · recruiting
NCT07417189 — A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) · Phase 1, PHASE2 · recruiting
NCT07228247 — A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06504368 — Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors · Phase 1 · recruiting
NCT05861895 — HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors · Phase 1 · recruiting

Other Wuxi People's Hospital trials

Trials by the same sponsor.

NCT06430502 — Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced · NA · recruiting
NCT06240767 — Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutrophils · Phase 1 · unknown
NCT06404528 — Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours · NA · recruiting
NCT06430515 — The Clinical Efficacy and Safety of Intratumoral Injection of Chemotherapy for Advanced Solid Tumors · NA · recruiting
NCT05523050 — Active Surgical Intervention on Crohn's Disease · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05747339 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wuxi People's Hospital
Last refreshed: 13 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05747339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing